Canaccord lowered the firm’s price target on Evolent Health (EVH) to $16 from $23 and keeps a Buy rating on the shares. The firm looks at 2025 to be a year to re-base and de-risk the business and then to return to mid-teens revenue growth and roughly 20% adj-EBITDA growth for several years to come. Canaccord noted the company’s recent business update which omitted a 4Q pre-release and initial 2025 guidance.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EVH:
- Evolent Health price target lowered to $15 from $20 at Truist
- Evolent Health price target lowered to $20 from $29 at BTIG
- Evolent Health price target lowered to $12 from $16 at Stephens
- Evolent Health price target lowered to $14 from $27 at UBS
- Evolent Health reiterates long-term outlook, says FY25 guide coming February 20